Elsevier

The Lancet

Volume 247, Issue 6403, 18 May 1946, Pages 724-731
The Lancet

ORIGINAL ARTICLES
LIPODYSTROPHY AND HEPATOMEGALY WITH DIABETES, LIPÆMIA, AND OTHER METABOLIC DISTURBANCES: A CASE THROWING NEW LIGHT ON THE ACTION OF INSULIN

https://doi.org/10.1016/S0140-6736(46)90528-4Get rights and content

First page preview

First page preview
Click to open first page preview

References (0)

Cited by (135)

  • Genetics of lipodystrophy syndromes

    2021, Presse Medicale
    Citation Excerpt :

    Cautions should be taken when analyzing variants in a given gene, when there is no robust evidence to support the gene-disease association. For example, in the case of LS, evidence to support the implication of ADRA2A is currently limited [3] and clear association between the alpha-2-adrenergic receptor and disease has not been yet established. Another example is that of the PLIN1 gene encoding perilipin-1, a key protein for lipid droplet formation and triglyceride metabolism.

  • Lipodystrophy

    2018, Encyclopedia of Endocrine Diseases
  • Thematic review series: Lipid droplet synthesis and metabolism: From yeast to man - Seipin: From human disease to molecular mechanism

    2012, Journal of Lipid Research
    Citation Excerpt :

    However, with more extreme fat loss, the patient's metabolic condition becomes more severe. The first thorough characterization of the effects of whole-body, or generalized, lipodystrophy was published by R. D. Lawrence in 1946 (3). This syndrome was often termed “lipoatrophic diabetes” because of the striking metabolic picture that accompanies fat loss.

  • Monogenic severe insulin resistance syndromes

    2005, Revue de Medecine Interne
View all citing articles on Scopus

The Oliver-Sharpey lectures delivered at the Royal College of Physicians of London on March 19 and 20, 1946.

View full text